$-0.38
(Market cap
$8,510 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
12.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-14.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.8
-
Face value
--
-
Shares outstanding
206,552,682
6 Years Aggregate
CFO
$-559.31 Mln
EBITDA
$-527.71 Mln
Net Profit
$-678.25 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| 60.6 | 3.4 | 22.6 | 177.9 | 22.3 | 37.4 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| 2.6 | -41.0 | 137.4 | 108.3 | -81.6 | 191.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
|
40.8 | 8,510.0 | 7.1 | -538.2 | -7,595.7 | -62.5 | -- | 12.3 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Immunovant Inc (IMVT)
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for... graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. Read more
-
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
-
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
-
Headquarters
Durham, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immunovant Inc (IMVT)
What is the current share price of Immunovant Inc (IMVT) Today?
The share price of Immunovant Inc (IMVT) is $40.82 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Immunovant Inc (IMVT) has given a return of 22.27% in the last 3 years.
What is the current PB & PE ratio of Immunovant Inc (IMVT)?
Since, TTM earnings of Immunovant Inc (IMVT) is negative, P/E ratio is not available.
The P/B ratio of Immunovant Inc (IMVT) is 12.31 times as on 28-Aug-2026, a 138 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-10.01 |
5.94 |
2025 |
-6.26 |
3.66 |
2024 |
-18.11 |
7.60 |
2023 |
-9.53 |
5.55 |
2022 |
-4.09 |
1.36 |
What is the 52 Week High and Low of Immunovant Inc (IMVT)?
The 52-week high and low of Immunovant Inc (IMVT) are Rs 45.35 and Rs 14.58 as of 01-Sep-2026.
What is the market cap of Immunovant Inc (IMVT)?
Immunovant Inc (IMVT) has a market capitalisation of $ 8,510 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immunovant Inc (IMVT)?
Before investing in Immunovant Inc (IMVT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.